Skip Navigation

European Heart Journal 1992 13(1):115-119;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by WELLER, A. H.
Right arrow Articles by HUBER, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WELLER, A. H.
Right arrow Articles by HUBER, S. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

Polyclonal immunoglobulin therapy protects against cardiac damage in experimental coxsackievirus-induced myocarditis

A. H. WELLER*, M. HALL* and S. A. HUBER{dagger},

*Department of Nutritional Sciences, University of Vermont Burlington Vermont 05405, U.S.A.
{dagger}Department of Pathology, University of Vermont, Burlington Vermont 05405, U.S.A.

Received 9 August 1990; revised 21 February 1991; .

Correcpondence: Dr S. A. Huber. Department of Pathology, University of Vermont. Burlington, Vermont 05405, U.S.A.

Abstract

Balb/c male mice infected i.p. with 2 x 105 plaque forming units (PFU) of coxsackievirus B3 (CVB3) develop severe mvocarditis 7 days later. Studies were performed to determine whether therapy with normal polyclonal immunoglobulin would prevent cardiac inflammation. Partially purified immunoglobulin was derived from pooled mouse serum by ammonium sulphate precipitation. Infected animals given either 100 or 1000 µg of this preparation for 2 days prior to infection showed greater than 50% reduction in myocarditis compared to control animals which were infected and given either phosphate buffered saline, human immunoglobulin ormonoclonal mouse IgG to an extraneous antigen. Protection did not depend upon inhibition of virus infection since cardiac viral titres were frequently equivalent in control and immunoglobulin-treated groups.

Key Words: Myocarditis • coxsackievirus B3 • autoimmunity • immunoglobulin • therapy • anti-idiotypes • mouse


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
K. Klingel, J.-J. Schnorr, M. Sauter, G. Szalay, and R. Kandolf
{beta}2-Microglobulin-Associated Regulation of Interferon-{gamma} and Virus-Specific Immunoglobulin G Confer Resistance Against the Development of Chronic Coxsackievirus Myocarditis
Am. J. Pathol., May 1, 2003; 162(5): 1709 - 1720.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Kishimoto, H. Takada, H. Kawamata, M. Umatake, and H. Ochiai
Immunoglobulin Treatment Prevents Congestive Heart Failure in Murine Encephalomyocarditis Viral Myocarditis Associated with Reduction of Inflammatory Cytokines
J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 645 - 651.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. M. McNamara, R. Holubkov, R. C. Starling, G. W. Dec, E. Loh, G. Torre-Amione, A. Gass, K. Janosko, T. Tokarczyk, P. Kessler, et al.
Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy
Circulation, May 8, 2001; 103(18): 2254 - 2259.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. M. McNamara, W. D. Rosenblum, K. M. Janosko, M. K. Trost, F. S. Villaneuva, A.J. Demetris, S. Murali, and A. M. Feldman
Intravenous Immune Globulin in the Therapy of Myocarditis and Acute Cardiomyopathy
Circulation, June 3, 1997; 95(11): 2476 - 2478.
[Abstract] [Full Text]

Home page
 CirculationHome page
H. Takada, C. Kishimoto, and Y. Hiraoka
Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model : Antiviral and Anti-inflammatory Effects
Circulation, September 15, 1995; 92(6): 1604 - 1611.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.